🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Invasive Cancer

Breast Cancer Survivorship Biorepository NCT05786664n/a1 site📍 Los Angeles University of Southern California · Tests: Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment, Survey Administration Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer NCT07844473NA1 site📍 Madinah King Faisal Specialist Hospital & Research Center · Tests: Super paramagnetic iron oxide bracketing injection A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder NCT07475806Phase 266 sites📍 Little Rock📍 Stanford📍 Chicago Astellas Pharma Global Development, Inc. · Tests: Enfortumab Vedotin, Pembrolizumab The Development of MASLD Among Survivors of Breast or Colorectal Cancer NCT07280143n/a1 site📍 Bern University of Bern Validation of the Oncoliq Test for the Early Detection of Breast Cancer. NCT07331506n/a1 site📍 Buenos Aires Oncoliq US Inc · Tests: Peripheral blood draw MAESTRO Study: Metabolic Imaging to Improve Patient-Specific Therapy Outcomes NCT04534543NA2 sites📍 Amsterdam📍 Utrecht Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: MRI/Spectroscopy Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy NCT07144319n/a8 sites📍 Tampa📍 Ann Arbor📍 New Brunswick Photocure Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer NCT07474519Phase 41 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Accelerometry, BCG Solution, BCG Solution, BCG Solution, Electronic Health Record Review Pre-therapeutic MRI Assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to Avoid Major Resectional Surgery NCT04103372NA23 sites📍 Reading📍 Amersham📍 London Imperial College London · Tests: MRI scan, Radiologist training Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection NCT06525571Phase 32 sites📍 Washington D.C.📍 Baltimore Johns Hopkins University · Tests: Cysview, Karl Storz D-Light C Photodynamic Diagnostic (PDD) system Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer NCT07327970n/a1 site📍 Incheon Young-Joon Kang · Tests: multi-modal foundation AI test A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) NCT07222488Phase 1, Phase 217 sites📍 Bakersfield📍 New Brunswick📍 Myrtle Beach Merck Sharp & Dohme LLC · Tests: MK-3120 Chemoablation for Low-Grade Bladder Cancer NCT07019220Phase 21 site📍 Vienna Ekaterina Laukhtina · Tests: Gemcitabine The Surveillance, Epidemiology, and End Results Database Program on Endometrial Cancer in the Italian Population NCT07558889n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677Phase 248 sites📍 Homewood📍 Little Rock📍 Murrieta Tyra Biosciences, Inc · Tests: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg Application of Single-Port Robot-Assisted Breast-Conserving Surgery Via Axillary Approach for Breast Cancer. NCT06738654NA2 sites📍 Chongqing📍 Chongqing Xu Yan · Tests: robot-surgery, traditional open surgry Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding NCT06365905n/a3 sites📍 Scottsdale📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Non-Interventional Study Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma NCT07068074Phase 3181 sites📍 Birmingham📍 Daphne📍 Fairhope ECOG-ACRIN Cancer Research Group · Tests: Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire … Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer NCT07003009NA1 site📍 Istanbul Istanbul Training and Research Hospital · Tests: Malign Lymph Node Washout, Benign Lymph Node Washout Use of Virtual Reality in Pain Management in Pediatric Oncology NCT05592132NA1 site📍 Saint-Denis Centre Hospitalier Universitaire de la Réunion · Tests: Virtual reality headset Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers NCT05205343n/a4 sites📍 Rochester📍 Houston📍 Tokyo M.D. Anderson Cancer Center · Tests: Standard of Care, Control Group Analysis of Urinary Methylation Patterns Via Liquid Biopsy as an Early Diagnosis Tool NCT06878027n/a1 site📍 Rome Regina Elena Cancer Institute The Clinical Effectiveness and Safety of Intravesical Mitomycin-C and Gemcitabine Sequential Therapy NCT06388720Phase 21 site📍 Goyang-si National Cancer Center, Korea · Tests: Mitomycin-C, gemcitabine Microbiome Testing for the Screening of Colorectal Cancer NCT06588166n/a1 site📍 Roma Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: Gut microbiome testing Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer NCT07187635NA7 sites📍 Nanchang📍 Guangzhou📍 Xingtai Tianjin Medical University Second Hospital · Tests: Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection) The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection NCT06287541NA1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Urine biomarker -Guided without reTURBT Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium NCT06694792n/a1 site📍 Milan IRCCS San Raffaele Non-inferiority Study of Contrast-enhanced Digital Mammography (CEDM) vs Magnetic Resonance Imaging (MRI) in Terms of Diagnostic Accuracy in Patients Undergoing Preoperative Staging of Established Invasive Breast Cancer NCT07071272NA1 site📍 Verona Azienda Ospedaliera Universitaria Integrata Verona · Tests: breast-MRI and CEM Pain Evaluation Across Robotic and Laparoscopic Surgery for Colorectal Procedures NCT07431892n/a1 site📍 Madrid Hospital Central de la Defensa Gómez Ulla
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy